MCID: ADL020
MIFTS: 12

Adult Malignant Mesenchymoma

Categories: Cancer diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Adult Malignant Mesenchymoma

MalaCards integrated aliases for Adult Malignant Mesenchymoma:

Name: Adult Malignant Mesenchymoma 12 72

Classifications:



External Ids:

Disease Ontology 12 DOID:5894
NCIt 50 C7947
UMLS 72 C0279548

Summaries for Adult Malignant Mesenchymoma

MalaCards based summary : Adult Malignant Mesenchymoma is related to mesenchymoma and malignant mesenchymoma. The drugs Mechlorethamine and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include lung.

Related Diseases for Adult Malignant Mesenchymoma

Diseases in the Mesenchymoma family:

Benign Mesenchymoma Malignant Mesenchymoma
Adult Malignant Mesenchymoma

Diseases related to Adult Malignant Mesenchymoma via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 mesenchymoma 10.0
2 malignant mesenchymoma 10.0

Symptoms & Phenotypes for Adult Malignant Mesenchymoma

Drugs & Therapeutics for Adult Malignant Mesenchymoma

Drugs for Adult Malignant Mesenchymoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 43)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
2
Lenograstim Approved, Investigational Phase 3 135968-09-1
3
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
4
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
5
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
6
Dactinomycin Approved, Investigational Phase 3 50-76-0 457193 2019
7
Morphine Approved, Investigational Phase 3 57-27-2 5288826
8
Mesna Approved, Investigational Phase 3 3375-50-6 598
9
Topotecan Approved, Investigational Phase 3 123948-87-8, 119413-54-6 60700
10
Trabectedin Approved, Investigational Phase 2, Phase 3 114899-77-3 108150
11
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
12
Camptothecin Experimental Phase 3 7689-03-4
13 Immunosuppressive Agents Phase 3
14 Tubulin Modulators Phase 3
15 Antineoplastic Agents, Phytogenic Phase 3
16 Anti-Infective Agents Phase 3
17 Nucleic Acid Synthesis Inhibitors Phase 3
18 Antimitotic Agents Phase 3
19 Immunologic Factors Phase 3
20 Antirheumatic Agents Phase 3
21 topoisomerase I inhibitors Phase 3
22 Adjuvants, Immunologic Phase 3
23 Alkylating Agents Phase 2, Phase 3
24 Antineoplastic Agents, Alkylating Phase 2, Phase 3
25
Liposomal doxorubicin Phase 2, Phase 3 31703
26 Anti-Bacterial Agents Phase 2, Phase 3
27 Antibiotics, Antitubercular Phase 2, Phase 3
28 Topoisomerase Inhibitors Phase 2, Phase 3
29
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
30
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
31
Ifosfamide Approved Phase 2 3778-73-2 3690
32
Irinotecan Approved, Investigational Phase 2 100286-90-6, 97682-44-5 60838
33
Etoposide Approved Phase 2 33419-42-0 36462
34
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
35 Angiogenesis Inhibitors Phase 2
36 Protein Kinase Inhibitors Phase 2
37 Angiogenesis Modulating Agents Phase 2
38 Imatinib Mesylate Phase 1, Phase 2 220127-57-1 123596
39
Isophosphamide mustard Phase 2 0
40 Etoposide phosphate Phase 2
41 razoxane Phase 2
42 Cardiotonic Agents Phase 2
43 Protective Agents Phase 2

Interventional clinical trials:

(show all 20)
# Name Status NCT ID Phase Drugs
1 A Phase III Randomized Study of Preoperative Radiotherapy Plus Surgery Versus Surgery Alone for Patients With Retroperitoneal Sarcoma (RPS) Unknown status NCT01344018 Phase 3
2 Randomised Trial of Post-Operative Radiotherapy Given to Adult Patients With Extremity Soft Tissue Sarcoma [VORTEX] Completed NCT00423618 Phase 3
3 METASTASECTOMY AND CHEMOTHERAPY FOR LUNG METASTASES FROM SOFT TISSUE SARCOMA: A RANDOMIZED PHASE III STUDY (AN INTERGROUP STUDY WITH THE SCANDINAVIAN SARCOMA GROUP) Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
4 Actinomycin D and Vincristine With or Without Radiation Therapy, for Newly Diagnosed Patients With Low-Risk Rhabdomyosarcoma or Undifferentiated Sarcoma: IRS-V Protocol Completed NCT00002995 Phase 3 cyclophosphamide;vincristine sulfate
5 RANDOMISED TRIAL OF ADJUVANT CHEMOTHERAPY WITH HIGH-DOSE DOXORUBICIN, IFOSFAMIDE AND LENOGRASTIM IN HIGH GRADE SOFT TISSUE SARCOMA Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
6 Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) Versus VAC Alternating With Vincristine and Irinotecan (VI) for Patients With Intermediate-Risk Rhabdomyosarcoma (RMS) Completed NCT00354835 Phase 3 Irinotecan Hydrochloride;Cyclophosphamide;Vincristine Sulfate
7 Intensive Multi-Agent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide (IE) and Vincristine/Doxorubicin/Cyclophosphamide (VDC) for Patients With High-Risk Rhabdomyosarcoma Completed NCT00354744 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;irinotecan hydrochloride;vincristine sulfate
8 Randomized Study of Vincristine, Actinomycin-D, and Cyclophosphamide (VAC) Versus VAC Alternating With Vincristine, Topotecan and Cyclophosphamide for Patients With Intermediate Risk Rhabdomyosarcoma Completed NCT00003958 Phase 3 vincristine sulfate;cyclophosphamide;topotecan hydrochloride
9 TRUSTS: A Phase IIB/III Multicenter Study Comparing the Efficacy of TRabectedin Administered as a 3-Hour or 24-Hour Infusion to Doxorubicin in Patients With Advanced or Metastatic Untreated Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
10 Randomized Phase II Study of Brostallicin (PNU-166196A) Versus Doxorubicin as First Line Chemotherapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
11 Phase II Evaluation of Temodal (Temozolomide, Schering) in Previously Treated Advanced Sarcomas Unknown status NCT00003718 Phase 2 temozolomide
12 Phase II Study on ET-743 in Advanced Soft Tissue Sarcomas of the Adult Completed NCT00003939 Phase 2 trabectedin
13 A Multicenter Phase II Study of Continuous Dosing of Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
14 Dose Finding and Phase II Study of STI 571 in Advanced Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
15 Multicenter Parallel Phase II Trial of BI 2536 Administered as One Hour IV Infusion Every 3 Weeks in Defined Cohorts of Patients With Various Solid Tumors. A New Drug Screening Program of the EORTC Network of Core Institutions (NOCI) Completed NCT00526149 Phase 2 BI 2536
16 A Phase II "Up-Front Window Study" of Irinotecan (CPT-11) Followed by Multimodal, Multiagent, Therapy for Selected Children and Adolescents With Newly Diagnosed Stage 4/Clinical Group IV Rhabdomyosarcoma: An IRS-V Study Completed NCT00003955 Phase 2 cyclophosphamide;irinotecan hydrochloride;vincristine sulfate
17 A Pilot Phase II Trial Of Irinotecan Plus Carboplatin, And Irinotecan Maintenance Therapy (High-Risk Patients Only), Integrated Into The Upfront Therapy Of Newly Diagnosed Patients With Intermediate - And High-Risk Rhabdomyosarcoma Active, not recruiting NCT00077285 Phase 2 carboplatin;cyclophosphamide;dexrazoxane hydrochloride;doxorubicin hydrochloride;etoposide;ifosfamide;irinotecan hydrochloride;vincristine sulfate
18 Phase II Study of Preoperative Intensity-Modulated Radiation Therapy for Soft-Tissue Sarcomas Terminated NCT00740597 Phase 2
19 Phase I Study To Determine The Safety Of Caelyx (Doxorubin HCI, Pegylated Liposomal) In Combination With Ifosfamide In Previously Untreated Adult Patients With Advanced And/Or Metastatic Soft Tissues Sarcomas Completed NCT00030784 Phase 1 ifosfamide;pegylated liposomal doxorubicin hydrochloride
20 VORTEX-BIOBANK: Prospective Sample Collection for the VORTEX Randomised Radiotherapy Trial in Patients With Extremity Soft Tissue Sarcoma [VORTEX BIOBANK] Unknown status NCT00900211

Search NIH Clinical Center for Adult Malignant Mesenchymoma

Genetic Tests for Adult Malignant Mesenchymoma

Anatomical Context for Adult Malignant Mesenchymoma

MalaCards organs/tissues related to Adult Malignant Mesenchymoma:

41
Lung

Publications for Adult Malignant Mesenchymoma

Variations for Adult Malignant Mesenchymoma

Expression for Adult Malignant Mesenchymoma

Search GEO for disease gene expression data for Adult Malignant Mesenchymoma.

Pathways for Adult Malignant Mesenchymoma

GO Terms for Adult Malignant Mesenchymoma

Sources for Adult Malignant Mesenchymoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....